Randomized evaluation of fibrinogen vs placebo in complex cardiovascular surgery (REPLACE) : a double-blind phase III study of haemostatic therapy

Show full item record



Permalink

http://hdl.handle.net/10138/164753

Citation

Rahe-Meyer , N , Levy , J H , Mazer , C D , Schramko , A , Klein , A A , Brat , R , Okita , Y , Ueda , Y , Schmidt , D S , Ranganath , R & Gill , R 2016 , ' Randomized evaluation of fibrinogen vs placebo in complex cardiovascular surgery (REPLACE) : a double-blind phase III study of haemostatic therapy ' , British Journal of Anaesthesia , vol. 117 , no. 1 , pp. 41-51 . https://doi.org/10.1093/bja/aew169

Title: Randomized evaluation of fibrinogen vs placebo in complex cardiovascular surgery (REPLACE) : a double-blind phase III study of haemostatic therapy
Author: Rahe-Meyer, N.; Levy, J. H.; Mazer, C. D.; Schramko, A.; Klein, A. A.; Brat, R.; Okita, Y.; Ueda, Y.; Schmidt, D. S.; Ranganath, R.; Gill, R.
Contributor: University of Helsinki, Anestesiologian yksikkö
Date: 2016-07
Language: eng
Number of pages: 11
Belongs to series: British Journal of Anaesthesia
ISSN: 0007-0912
URI: http://hdl.handle.net/10138/164753
Abstract: Background: Single-dose human fibrinogen concentrate (FCH) might have haemostatic benefits in complex cardiovascular surgery. Methods: Patients undergoing elective aortic surgery requiring cardiopulmonary bypass were randomly assigned to receive FCH or placebo. Study medication was administered to patients with a 5 min bleeding mass of 60-250 g after separation from bypass and surgical haemostasis. A standardized algorithm for allogeneic blood product transfusion was followed if bleeding continued after study medication. Results: 519 patients from 34 centres were randomized, of whom 152 (29%) met inclusion criteria for study medication. Median (IQR) pretreatment 5 min bleeding mass was 107 (76-138) and 91 (71-112) g in the FCH and placebo groups, respectively (P=0.13). More allogeneic blood product units were administered during the first 24 h after FCH, 5.0 (2.0-11.0), when compared with placebo, 3.0 (0.0-7.0), P=0.026. Fewer patients avoided transfusion in the FCH group (15.4%) compared with placebo (28.4%), P=0.047. The FCH immediately increased plasma fibrinogen concentration and fibrin-based clot strength. Adverse event rates were comparable in each group. Conclusions: Human fibrinogen concentrate was associated with increased allogeneic blood product transfusion, an unexpected finding contrary to previous studies. Human fibrinogen concentrate may not be effective in this setting when administered according to 5-minute bleeding mass. Low bleeding rates and normal-range plasma fibrinogen concentrations before study medication, and variability in adherence to the complex transfusion algorithm, may have contributed to these results.
Subject: blood, coagulation
fibrinogen
haemorrhage
surgery, cardiovascular
CARDIOPULMONARY BYPASS
CONTROLLED-TRIAL
CARDIAC-SURGERY
BLOOD-LOSS
CONCENTRATE
MANAGEMENT
LEVEL
3126 Surgery, anesthesiology, intensive care, radiology
Rights:


Files in this item

Total number of downloads: Loading...

Files Size Format View
41.full.pdf 294.6Kb PDF View/Open

This item appears in the following Collection(s)

Show full item record